1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatic Encephalopathy - Pipeline Review, H1 2016

Hepatic Encephalopathy - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 63 pages

Hepatic Encephalopathy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Hepatic Encephalopathy - Pipeline Review, H1 2016’, provides an overview of the Hepatic Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
- The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects
- The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hepatic Encephalopathy - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatic Encephalopathy Overview 6
Therapeutics Development 7
Pipeline Products for Hepatic Encephalopathy - Overview 7
Hepatic Encephalopathy - Therapeutics under Development by Companies 8
Hepatic Encephalopathy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Hepatic Encephalopathy - Products under Development by Companies 13
Hepatic Encephalopathy - Companies Involved in Therapeutics Development 14
Alfa Wassermann S.p.A 14
Cosmo Pharmaceuticals S.p.A 15
Horizon Pharma Plc 16
KannaLife Sciences, Inc. 17
Ocera Therapeutics, Inc. 18
Rebiotix Inc. 19
Spherium Biomed S.L. 20
Umecrine Cognition AB 21
Hepatic Encephalopathy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
glycerol phenylbutyrate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
GR-3027 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
KLS-13019 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
ornithine phenylacetate - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
RBX-2477 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
rifamycin CR - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
rifaximin - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
THDP-17 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Hepatic Encephalopathy - Recent Pipeline Updates 45
Hepatic Encephalopathy - Dormant Projects 54
Hepatic Encephalopathy - Product Development Milestones 55
Featured News and Press Releases 55
Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy 55
Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy 55
Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy 56
Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019 57
Apr 20, 2015: Lupin Launches Zaxine in Canada 58
Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy 58
Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin 59
Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada 59
Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology 60
Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables
Number of Products under Development for Hepatic Encephalopathy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Comparative Analysis by Unknown Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H1 2016 14
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2016 15
Hepatic Encephalopathy - Pipeline by Horizon Pharma Plc, H1 2016 16
Hepatic Encephalopathy - Pipeline by KannaLife Sciences, Inc., H1 2016 17
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H1 2016 18
Hepatic Encephalopathy - Pipeline by Rebiotix Inc., H1 2016 19
Hepatic Encephalopathy - Pipeline by Spherium Biomed S.L., H1 2016 20
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Hepatic Encephalopathy Therapeutics - Recent Pipeline Updates, H1 2016 45
Hepatic Encephalopathy - Dormant Projects, H1 2016 54

List of Figures
Number of Products under Development for Hepatic Encephalopathy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Targets, H1 2016 23
Number of Products by Mechanism of Actions, H1 2016 25
Number of Products by Stage and Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.